Ocera Therapeutics Completes First In Human Studies With OCR-002 For The Treatment Of Hyperammonemia And Hepatic Encephalopathy
Links shared publicly online about this topic.
- 651total visits
Ocera Therapeutics Completes First In Human Studies With OCR-002 For The Treatment Of Hyperammonemia And Hepatic Encephalopathy
Ocera Therapeutics, Inc. announced that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and patients
View full resource at medicalnewstoday.com
Tags: Pharmacokinetics, Safety
Most Recently Shared on December 16, 2010 at 7:05 pm By:
Ocera Therapeutics Completes First In Human Studies With OCR-002 For The Treatment Of Hyperammonemia And Hepatic Encep... http://mnt.to/3P9W
Also Shared By:
Advertisement
MNT Liver Disease
@mnt_liver
Ocera Therapeutics Completes First In Human Studies With OCR-002 For The Treatment Of Hyperammonemia And Hepatic Encep... http://mnt.to/3P9W
1 year ago...